Navigation Links
Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
Date:2/25/2008

BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, is pleased to announce the appointment of Hsiao Dee Lieu, M.D., F.A.C.C. as its Vice President of Clinical Research.

"I am delighted to welcome Dr. Lieu to Nile. Dr. Lieu has extensive cardiovascular clinical development experience, which should be immediately beneficial to Nile and our CD-NP and 2NTX-99 development programs," said Peter Strumph, Chief Executive Officer of Nile.

Dr. Lieu has significant translational experience, which includes molecular cardiology research through clinical execution of large multinational Phase III clinical trials. Prior to joining Nile, Dr. Lieu served as Director of Clinical Development for Portola Pharmaceuticals, Inc., where he led the global development of a large ADP antagonist program in acute coronary syndrome. In this role, Dr. Lieu was responsible for the overall clinical development plan of intravenous and oral molecules from early- to late-stage development. He led the development of trial designs (Phase I to Phase III) with successful execution of Phase I and II trials. He has managed interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe.

Before joining Portola, Dr. Lieu worked at CV Therapeutics, Inc. (CVTX), where he served as Director, Clinical Research and Development. In this role, he led the clinical development program for regadenoson, which included two large multinational successful Phase III trials. Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (UCSF) conducting molecular cardiology research in gene manipulation and induction of cardiomyopathy and atherosclerosis regression.

Dr. Lieu currently serves as Assistant Clinical Professor of Medicin
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
2. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards
7. Meredith Martin Addy Named One of Top 10 Illinois Super Lawyers for 2008
8. Carl Hull Named President and Chief Operating Officer of Gen-Probe
9. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
10. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
11. Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 Illinois Super Lawyers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... ANY LAB TEST NOW(R), the first retail direct-access ... partnered with Atherotech, Inc., a Birmingham, Alabama-based CLIA-laboratory to ... an affordable price. The VAP Cholesterol Test is an ... people at risk and is the first cholesterol test ...
... Belgium, May 14 , - ... Accordance With the Law of May 2, 2007 , ... company,focused on the discovery and development of innovative treatments for ... update for,the three month period ending 31 March, 2009. , ...
... Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... in a Phase 2 clinical trial of its lead ...
Cached Biology Technology:VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3ThromboGenics NV: Business Update 2ThromboGenics NV: Business Update 3ThromboGenics NV: Business Update 4ThromboGenics NV: Business Update 5ThromboGenics NV: Business Update 6ThromboGenics NV: Business Update 7VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
(Date:7/10/2014)... New research from The University of Texas Health ... GameKeep it Real (IYG), a health education program designed ... can significantly reduce dating violence behaviors among minority youth. ... Prevention, 10 percent of high school youth are victims ... more than 20 percent are victims of emotional dating ...
(Date:7/10/2014)... predict that western Lake Erie will have a significant ... 2014 bloom season in late summer. However, the predicted ... intense bloom, and considerably less than the record-setting 2011 ... western basin and are classified by an estimate of ... , Harmful algal blooms (HABs) were common in western ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3
... team of Duke Medicine researchers has engineered cartilage from induced ... use in tissue repair and studies into cartilage injury and ... in the journal the Proceedings of the National Academy ... or iPSCs, may be a viable source of patient-specific articular ...
... The Journal of Cell Biology shows how ... nerve cells to help prevent neurodegeneration. The findings could pave ... in patients with neurodegenerative diseases. In Lou Gehrig,s ... in stages, with axons deteriorating first and the cells themselves ...
... who have lost a substantial amount of weight after ... their siblings who were born before the weight loss ... weight loss that occur after the surgery have a ... according to a new study presented at the Canadian ...
Cached Biology News:Duke researchers engineer cartilage from pluripotent stem cells 2Stay-at-home transcription factor prevents neurodegeneration 2Obese moms give birth to heart healthier kids following bariatric surgery 2Obese moms give birth to heart healthier kids following bariatric surgery 3
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: